Open AccessThe Efficacy of Topical 0.03% Tacrolimus Dermatologic Ointment in Treatment of Vernal Keratoconjunctivitis
Author(s) -
Muhammad Adnan,
Amena Masrur,
Fatima Khan,
Ali Tayyab
Publication year - 2021
Publication title -
life and science
Language(s) - English
Resource type - Journals
eISSN - 2708-2970
pISSN - 2521-0475
DOI - 10.37185/lns.1.1.142
Subject(s) - medicine , tacrolimus , vernal keratoconjunctivitis , dermatology , antihistamine , palpebral fissure , ketotifen , topical medication , surgery , ophthalmology , anesthesia , transplantation , asthma , glaucoma
Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernalkeratoconjunctivitis.Study Design: Cross-sectional.Place and Duration of Study: The study was conducted at Eye Donors Association Hospital, Wah Cantonmentfrom August 2019 to January 2020.Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were includedin this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornixonce at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine(0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief.The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinicalsigns were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized gradingsheet.Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baselinescores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dotsafter 8 weeks of treatment.Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment ofvernal kerato-conjunctivitis.